Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
The aim of this pilot-study is to investigate the effect of Vildagliptin in comparison to glimepiride on beta cell function and the cardiovascular risk profile in patients previously treated with Metformin monotherapy.
Epistemonikos ID: 2bf57011087e3f8dcb3a93856983e3717290a6d4
First added on: May 10, 2024